GLP-1 Receptor Agonist
Buy Semaglutide 6mg
The original blockbuster weight loss peptide. FDA-approved as Ozempic/Wegovy. −17.4% body weight over 68 weeks. The foundation of the GLP-1 revolution.
≥98% Purity
HPLC Verified
Research Grade
Lyophilized
Fast Shipping
Free $200+
Specifications
Mechanism of Action
Hypothalamic Appetite Suppression
Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in the hypothalamus and brainstem (area postrema), reducing appetite and food intake. Brain imaging studies show reduced activation of reward-related food cues in semaglutide-treated subjects.
Gastric Emptying Delay
GLP-1 receptor activation slows gastric emptying, extending the feeling of fullness after meals. This mechanical satiety effect operates independently of appetite suppression, providing dual control of caloric intake.
Glucose-Dependent Insulin Potentiation
Semaglutide potentiates insulin secretion from pancreatic beta cells in a glucose-dependent manner — meaning it only increases insulin when blood glucose is elevated, reducing hypoglycemia risk. It also suppresses inappropriate glucagon secretion.
Cardiovascular Protection (SELECT Trial)
The SELECT cardiovascular outcomes trial (2023, 17,604 participants) showed semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% in people with obesity and established cardiovascular disease — making it the first weight loss drug with proven CV mortality benefit.
Research Findings
STEP-1 Phase 3 Trial
1,961 participants, 68 weeks. Semaglutide 2.4mg achieved −14.9% body weight vs −2.4% placebo. 86% achieved ≥5% weight loss; 50% achieved ≥15% weight loss.
Wilding et al., New England Journal of Medicine (2021)
SELECT Cardiovascular Outcomes Trial
17,604 participants with obesity and established CV disease. Semaglutide 2.4mg reduced 3-point MACE (CV death, non-fatal MI, non-fatal stroke) by 20% vs placebo — the first anti-obesity drug with proven CV outcomes benefit.
Lincoff et al., New England Journal of Medicine (2023)
SUSTAIN-6 (Diabetes + CV Outcomes)
3,297 participants with T2D. 0.5mg and 1mg doses reduced major CV events by 26% and significantly reduced new or worsening nephropathy.
Marso et al., New England Journal of Medicine (2016)
Preclinical Safety Data
Semaglutide has the most extensive human safety dataset in the GLP-1 class — Phase 3 trials with >10,000 participants and post-market data from millions of approved users. FDA approved since 2017 (Ozempic) and 2021 (Wegovy). Primary safety concerns are GI-related. SELECT trial (17,604 participants) additionally validated cardiovascular safety with a demonstrated protective effect.
Research Dosing Protocols
From published literature — for research reference only.
Standard Weekly Injection
0.25–2.4 mg/week
Once weekly
FDA Wegovy dosing: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, then 2.4mg maintenance. Subcutaneous.
Low Entry Point
0.25 mg/week
Once weekly for 4 weeks, then escalate
Starting at 0.25mg significantly reduces GI side effects during adaptation. Essential for first-time GLP-1 users.
Reconstitution Guide
- 1
Allow vial to reach room temperature (10 minutes).
- 2
Draw 1–2 mL bacteriostatic water into insulin syringe.
- 3
Inject slowly down the vial wall — not onto the powder.
- 4
Swirl gently until dissolved — do not shake.
- 5
5mg vial + 2mL BAC water = 2.5mg/mL. For 0.5mg dose, draw 0.2mL.
- 6
Refrigerate at 4°C after reconstitution. Use within 4 weeks.
Stacking Guide
BPC-157
GI tolerability is the main challenge with semaglutide. BPC-157's gastroprotective effects — reversing GI inflammation and protecting mucosal integrity — may reduce nausea and GI discomfort during the dose escalation phase.
GHK-Cu
$50.00Significant caloric restriction during semaglutide protocols can affect skin quality. GHK-Cu activates collagen synthesis genes and maintains skin elasticity — a key cosmetic consideration during aggressive fat loss.
Frequently Asked Questions
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is FDA-approved as Ozempic (weekly injection, T2D), Rybelsus (daily oral tablet, T2D), and Wegovy (weekly injection, obesity). It achieved −17.4% body weight in Phase 3 trials and has demonstrated cardiovascular mortality benefit in the SELECT trial.
How does Semaglutide compare to Tirzepatide?
Head-to-head SURMOUNT-5 trial (2025) showed tirzepatide achieved −20.2% vs semaglutide's −13.7% weight loss over 72 weeks. Semaglutide has more long-term cardiovascular outcomes data (SELECT trial, 17,604 participants). For pure weight loss magnitude, tirzepatide is superior.
What is the half-life of Semaglutide?
Approximately 7 days, achieved through fatty acid chain attachment enabling albumin binding. This half-life is what allows once-weekly dosing — previous GLP-1 agonists (exenatide, liraglutide) required daily injection.
What are Semaglutide's side effects?
Primary GI effects: nausea (40–44%), diarrhea (30%), vomiting (24%), constipation. These are dose-dependent and highest during escalation. Rare but serious: pancreatitis, gallbladder disease. Thyroid C-cell carcinoma risk has been observed in rodents but not confirmed in human trials.
How should research-grade Semaglutide be stored?
Lyophilized at −20°C for up to 24 months. After reconstitution: 4°C, use within 4 weeks. Protect from light. Do not freeze reconstituted peptide.
Research Disclosure: All products on this page are for laboratory research purposes only. They are not FDA-approved for human consumption, injection, or therapeutic use. Research findings cited are from preclinical and clinical studies and should not be interpreted as medical advice. Always consult a licensed healthcare provider.
Related Products
BPC-157 + TB-500 Blend 20mg
Buy BPC-157 + TB-500 Blend 20mg online — research-grade lyophilized peptide for laboratory use. Body Protection Compound-157 (15-amino-acid pentadecapeptide). ≥98% HPLC purity verified.
CAS: 137525-51-0
Semaglutide 6mg
$79.99